The majority of patients had no rectal bleeding at all and also had fewer daily bowel movements at about 4 years .* Clinical trials of STELARA included patients who failed or were intolerant to other medications, including a biologic, prior to STELARA
Consult your physician before beginning any new treatment protocol
Possible significance and implications for novel mediator
Once we have a clear picture of root causes whether its SIBO, candida, parasites, food sensitivities, or a combination we build a layered protocol: remove the offending agents, support digestion and detoxification, and then deploy targeted peptides to accelerate mucosal repair
Additionally, individuals with autoimmune or gastrointestinal disorders, such as pernicious anemia, celiac, or Crohns disease, are more likely to be at risk of deficiency